Key Points
- Benjamin Hohl, Enliven's CFO, sold 10,000 shares on March 6 at an average price of $29.58 for roughly $295,800, cutting his direct holding to 51,000 shares (a 16.39% decrease).
- Enliven reported quarterly EPS of ($0.48), missing estimates of ($0.42), while analysts hold a consensus Moderate Buy rating with a $41 consensus price target.
- The stock has a market cap of $1.81 billion, a negative P/E (-16.26), a 50-day/200-day moving average of $25.88/$22.02, and a 12‑month range of $13.30 to $30.78.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Enliven Therapeutics Stock Performance
ELVN opened at $30.24 on Wednesday. The firm has a market cap of $1.81 billion, a P/E ratio of -16.26 and a beta of 0.33. The business has a 50 day moving average price of $25.88 and a 200 day moving average price of $22.02. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.78.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
Several large investors have recently bought and sold shares of ELVN. Commodore Capital LP boosted its holdings in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock valued at $94,138,000 after purchasing an additional 17,809 shares during the period. Vestal Point Capital LP raised its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company's stock valued at $54,111,000 after buying an additional 418,673 shares during the period. Vanguard Group Inc. grew its position in Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock worth $52,260,000 after buying an additional 142,378 shares in the last quarter. Finally, State Street Corp increased its stake in Enliven Therapeutics by 9.1% during the fourth quarter. State Street Corp now owns 1,052,862 shares of the company's stock valued at $16,214,000 after acquiring an additional 87,725 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have issued reports on ELVN. Wall Street Zen cut shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.00.
Check Out Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
